An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Should You Try MOTS c and BPC 157 Longevity Peptides? Separating Truth from Hype with Human Data Studies When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions